VRT 0.99% $6.15 virtus health limited

A straw hat in winter, possibly..., page-16

  1. 4,960 Posts.
    lightbulb Created with Sketch. 33
    The VRT result was, IMO, quite mixed.

    The BAD
    1. Loss of market share of 1.8% and from the presentation, appears to have lost share for 4 years
    2. Revenue down and costs up gave a poor profit result
    3. Had to "borrow" cash to pay dividend. i.e. - cash flow was not enough to pay CAPEX and dividends.
    4. page 22 of the presentation reported net capex which is quite misleading, it paints a picture of positve cash flow which, IMO, is wrong.

    The GOOD
    1. Dignostics had a great year with a 37% improvement in EBITDA
    2. Diversification of revenue is providing some buffer to the business
    3. Have taken steps to arrest market share decline - particularly in Vic.
    4. Plan for cost savings of $5m in FY18 is excellent news.

    The Ugly
    1. The balance sheet has 84% of the assets as intangibles.

    HT1
 
watchlist Created with Sketch. Add VRT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.